Delivery Order SPE2DB24D1205-SPE2DB25FCZCA
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector, with a ceiling value of $6,165.34. The award, issued on July 28, 2025, is a firm fixed price delivery order with an ultimate completion date of August 18, 2025. This contract was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under...
- The Defense Logistics Agency awarded a $6,165.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units. The contract, issued on July 22, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a $9,248.01 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/mL auto-injectors. The contract, awarded on July 18, 2025, with an ultimate completion date of August 8, 2025, utilizes firm fixed pricing with no set-aside designation. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a...
- The Defense Logistics Agency (DLA) awarded a Delivery Order contract to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector, with a ceiling value of $3,082.67. The contract was awarded on July 30, 2025, with an ultimate completion date of August 20, 2025, and utilizes firm fixed-price pricing under a non-competitive, non-set-aside arrangement. Performance will be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency (DLA) awarded a $15,413.35 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of August 21, 2025. This firm fixed-price contract, awarded on July 31, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $3,082.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with a completion date of August 21, 2025. This non-competitive award was issued to the company's corporate office located in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly for military and...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This is a firm fixed price contract with an ultimate completion date of August 14, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The contract carries no set-aside designation, indicating it was competitively awarded....
- The Defense Logistics Agency awarded a $6,165.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/mL auto-injector on August 4, 2025, with completion targeted for August 25, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation and...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZCADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 31, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract utilizing AmerisourceBergen's established indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support contract running through December 2026. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies an extensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems. Benlysta (belimumab) is a monoclonal antibody therapeutic used in the treatment of systemic lupus erythematosus, and this auto-injector formulation delivery supports the Defense Health Agency's pharmaceutical supply chain requirements. The delivery order demonstrates the contractor's continued capability to fulfill specialized medical product needs through the DLA's Pharmaceutical Prime Vendor Global Program infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 7/31/25 |